Vicebio Revenue and Competitors
Estimated Revenue & Valuation
- Vicebio's estimated annual revenue is currently $3.7M per year.
- Vicebio's estimated revenue per employee is $155,000
- Vicebio's total funding is $118M.
Employee Data
- Vicebio has 24 Employees.
- Vicebio grew their employee count by 100% last year.
Vicebio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
Vicebio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $9.1M | 59 | -9% | N/A | N/A |
#10 | $16.6M | 107 | 3% | N/A | N/A |
What Is Vicebio?
Vicebio is a clinical-stage biopharmaceutical company developing transformative multi-pathogen vaccines for respiratory viral infections.\nAt the core of our work is Vicebio’s groundbreaking Molecular Clamp Technology, which locks viral proteins in their optimal conformation. This innovation enables our vaccines to deliver a unique combination of broad protection, ready-to-use administration, and convenient manufacturing.\nOur lead program is a best-in-class multivalent vaccine targeting five respiratory diseases, positioning Vicebio as a leader in multipathogen respiratory vaccines.
keywords:N/A
$118M
Total Funding
24
Number of Employees
$3.7M
Revenue (est)
100%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.5M | 24 | -4% | N/A |
#2 | $3.5M | 24 | -14% | N/A |
#3 | $5.1M | 24 | -38% | N/A |
#4 | $2.4M | 24 | N/A | N/A |
#5 | $2.4M | 24 | N/A | N/A |